{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T18:49:26Z","timestamp":1791139766667,"version":"4.1.0"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T00:00:00Z","timestamp":1744848000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.semarthrit.2025.152737","type":"journal-article","created":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T15:47:17Z","timestamp":1744904837000},"page":"152737","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Biologic switching in psoriatic arthritis: Insights from real-world data and key risk factors"],"prefix":"10.1016","volume":"73","author":[{"given":"Amir","family":"Haddad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nili","family":"Stein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilan","family":"Feldhamer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnon Dov","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walid","family":"Saliba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devy","family":"Zisman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 2","key":"10.1016\/j.semarthrit.2025.152737_bib0001","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3899\/jrheum.2023-0522","article-title":"GRAPPA 2021 treatment recommendations for psoriatic arthritis","volume":"50","author":"Soriano","year":"2023","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2025.152737_bib0002","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1136\/ard-2024-225531","article-title":"EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update","volume":"83","author":"Gossec","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2025.152737_bib0003","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/art.40726","article-title":"Special article: 2018 American College of Rheumatology\/National Psoriasis Foundation guideline for the treatment of psoriatic arthritis","volume":"71","author":"Singh","year":"2019","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"10.1016\/j.semarthrit.2025.152737_bib0004","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s13075-017-1497-4","article-title":"The epidemiology of psoriatic arthritis in Israel - a population-based study","volume":"20","author":"Eder","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2025.152737_bib0005","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002681","article-title":"Long-term persistence of second-line biologics in psoriatic arthritis patients with prior TNF inhibitor exposure: a nationwide cohort study from the French health insurance database (SNDS)","volume":"8","author":"Pina Vegas","year":"2022","journal-title":"RMD Open"},{"issue":"11","key":"10.1016\/j.semarthrit.2025.152737_bib0006","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1136\/annrheumdis-2012-203018","article-title":"Switching between TNF inhibitors in psoriatic arthritis: data from the NOR-DMARD study","volume":"72","author":"Fagerli","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2025.152737_bib0007","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1002\/art.37876","article-title":"Clinical response, drug survival, and predictors thereof among 548 patients with psoriatic arthritis who switched tumor necrosis factor \u03b1 inhibitor therapy: results from the Danish Nationwide DANBIO Registry","volume":"65","author":"Glintborg","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2025.152737_bib0008","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1093\/rheumatology\/keq326","article-title":"Ten years with biologics: to whom do data on effectiveness and safety apply?","volume":"50","author":"Simard","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2025.152737_bib0009","doi-asserted-by":"crossref","first-page":"R52","DOI":"10.1186\/ar2670","article-title":"British Society for Rheumatology Biologics Register persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register","volume":"11","author":"Saad","year":"2009","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2025.152737_bib0010","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1136\/ard.2007.073544","article-title":"Efficacy and tolerability of anti-tumour necrosis factor therapy in psoriatic arthritis patients: results from the South Swedish Arthritis Treatment Group register","volume":"67","author":"Kristensen","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2025.152737_bib0011","doi-asserted-by":"crossref","first-page":"R29","DOI":"10.1186\/ar1881","article-title":"BIOBADASER Group switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period","volume":"8","author":"Gomez-Reino","year":"2006","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"10.1016\/j.semarthrit.2025.152737_bib0012","first-page":"81","article-title":"Effectiveness and feasibility associated with switching to a second or third TNF inhibitor in psoriatic arthritis: a cohort study from southern Sweden","volume":"43","author":"Kristensen","year":"2016","journal-title":"Rheumatol"},{"key":"10.1016\/j.semarthrit.2025.152737_bib0013","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1395968","article-title":"Drug survival superiority of tumor necrosis factor inhibitors and interleukin-17 inhibitors over Janus kinase inhibitors and interleukin-12\/23 inhibitors in German psoriatic arthritis outpatients: retrospective analysis of the RHADAR database","volume":"15","author":"Strunz","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.semarthrit.2025.152737_bib0014","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-75190-x","article-title":"Cycling versus swapping strategies with TNF-\u03b1 inhibitors and IL-17 inhibitors in psoriatic arthritis in clinical practice","volume":"14","author":"Lumetti","year":"2024","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.semarthrit.2025.152737_bib0015","doi-asserted-by":"crossref","first-page":"15","DOI":"10.55563\/clinexprheumatol\/1sx5yk","article-title":"Secukinumab real world drug retention compared to TNF-alpha inhibitors in psoriatic arthritis","volume":"40","author":"Eviatar","year":"2022","journal-title":"Clin Exp Rheumatol"},{"issue":"7","key":"10.1016\/j.semarthrit.2025.152737_bib0016","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1007\/s10067-016-3204-2","article-title":"Indirect comparisons of the efficacy of subsequent biological agents in patients with psoriatic arthritis with an inadequate response to tumor necrosis factor inhibitors: a meta-analysis","volume":"35","author":"Ungprasert","year":"2016","journal-title":"Clin Rheumatol"},{"issue":"4","key":"10.1016\/j.semarthrit.2025.152737_bib0017","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s12026-023-09366-4","article-title":"Efficacy and safety of IL-23 inhibitors in the treatment of psoriatic arthritis: a meta-analysis based on randomized controlled trials","volume":"71","author":"Huang","year":"2023","journal-title":"Immunol Res"},{"issue":"1","key":"10.1016\/j.semarthrit.2025.152737_bib0018","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s13075-021-02417-x","article-title":"Treatment persistence of biologics among patients with psoriatic arthritis","volume":"23","author":"Haddad","year":"2021","journal-title":"Arthritis Res Ther"},{"issue":"11","key":"10.1016\/j.semarthrit.2025.152737_bib0019","doi-asserted-by":"crossref","first-page":"4569","DOI":"10.1007\/s10067-021-05799-0","article-title":"Predictive factors for switching in patients with psoriatic arthritis undergoing anti-TNF\u03b1, anti-IL12\/23, or anti-IL17 drugs: a 15-year monocentric real-life study","volume":"40","author":"Lorenzin","year":"2021","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2025.152737_bib0020","doi-asserted-by":"crossref","unstructured":"Eder L, Mylvaganam S, Pardo Pardo J, Petkovic J, Strand V, Mease P, Colaco K. Sex-related differences in patient characteristics, and efficacy and safety of advanced therapies in randomised clinical trials in psoriatic arthritis: a systematic literature review and meta-analysis. Lancet Rheumatol, 5, 12, e716\u201327.","DOI":"10.1016\/S2665-9913(23)00264-3"},{"key":"10.1016\/j.semarthrit.2025.152737_bib0021","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2020-001498","article-title":"Effect of significant weight loss on disease activity: reason to implement this non-pharmaceutical intervention in daily clinical practice","volume":"7","author":"Weijers","year":"2021","journal-title":"RMD Open"},{"issue":"1","key":"10.1016\/j.semarthrit.2025.152737_bib0022","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.semarthrit.2017.02.001","article-title":"Switching biologics in the treatment of psoriatic arthritis","volume":"47","author":"Merola","year":"2017","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2025.152737_bib0023","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1136\/annrheumdis-2019-215386","article-title":"SPIRIT H2H study group. A head-to-head comparison of the efficacy and safety of Ixekizumab and adalimumab in biologicalna\u00efve patients with active psoriatic arthritis: 24-week results of a randomised, openlabel, blinded-assessor trial","volume":"79","author":"Mease","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2025.152737_bib0024","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1016\/S0140-6736(20)30564-X","article-title":"Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3B trial","volume":"395","author":"McInnes","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.semarthrit.2025.152737_bib0025","doi-asserted-by":"crossref","first-page":"2848","DOI":"10.1093\/rheumatology\/keab819","article-title":"New-onset inflammatory bowel diseases among IL-17 inhibitor-treated patients: results from the case-control MISSIL study","volume":"61","author":"Letarouilly","year":"2022","journal-title":"Rheumatology"},{"key":"10.1016\/j.semarthrit.2025.152737_bib0026","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1080\/03007995.2019.1620713","article-title":"Real-world incidence of inflammatory bowel disease among patients with other chronic inflammatory diseases treated with Interleukin-17A or phosphodiesterase 4 inhibitors","volume":"35","author":"Emond","year":"2019","journal-title":"Curr Med Res Opin"},{"issue":"7","key":"10.1016\/j.semarthrit.2025.152737_bib0027","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1136\/ard-2022-223715","article-title":"Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL surveillance","volume":"82","author":"Kristensen","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.semarthrit.2025.152737_bib0028","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1093\/rheumatology\/kex528","article-title":"The relationship between depression and biologic treatment response in rheumatoid arthritis: an analysis of the British Society for Rheumatology Biologics Register","volume":"57","author":"Matcham","year":"2018","journal-title":"Rheumatology (Oxford)."}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017225001088?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017225001088?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T01:58:11Z","timestamp":1751594291000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017225001088"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":28,"alternative-id":["S0049017225001088"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2025.152737","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biologic switching in psoriatic arthritis: Insights from real-world data and key risk factors","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2025.152737","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"152737"}}